Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Rhea-AI Summary

Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York City. The company, which specializes in developing proprietary antibody-based therapeutics, will deliver a corporate presentation on Thursday, February 6, 2025, from 9:00-9:25 AM EST.

The presentation will be accessible via webcast, and a replay will remain available for 90 days on Compass' Events page. This conference, scheduled for February 5-6, 2025, provides an opportunity for Compass to showcase its developments in treating multiple human diseases.

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Guggenheim Securities SMID Cap Biotech Conference taking place in New York City, NY February 5-6, 2025.

Presentation Details
Date: Thursday, February 6, 2025
Time: 9:00-9:25 AM EST
Webcast Link: https://wsw.com/webcast/guggen2/cmpx

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099

FAQ

When is Compass Therapeutics (CMPX) presenting at the Guggenheim SMID Cap Biotech Conference 2025?

Compass Therapeutics (CMPX) is scheduled to present on Thursday, February 6, 2025, from 9:00-9:25 AM EST.

How long will the CMPX Guggenheim Conference presentation replay be available?

The corporate presentation replay will be archived and available for 90 days on Compass' Events page.

Where can investors watch Compass Therapeutics' (CMPX) Guggenheim Conference presentation?

Investors can watch the presentation via webcast at https://wsw.com/webcast/guggen2/cmpx or access the replay through Compass' Events page.

What type of therapeutics is CMPX developing as presented at the Guggenheim Conference?

Compass Therapeutics is developing proprietary antibody-based therapeutics focused on treating multiple human diseases in the oncology sector.